Cell avidity measurement: a new accurate method to predict in vivo CAR T cell efficacy and minimize drug discovery timelines
In this application note, we describe the power of cell avidity in the search for improved CAR T cell therapies. We report on two publications from the lab of Dr. Marcela V. Maus (Harvard Medical School) that illustrate how cell avidity measurement with the z-Movi Cell Avidity Analyzer can accelerate the CAR T cell therapy development process against cancer by:
1. Enabling fast and reproducible assessment of CAR T cell therapy in vivo efficacy
2. Allowing quick selection of CAR T cell candidates earlier
3. Leading to faster more accurate CAR T cell drug discovery
